文献速递骨质疏松与代谢性骨病

停用地舒单抗后发生反跳相关椎体骨折女性的24个月随访:单中心病例系列

Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
PubMed 文献 · Osteoporos Int · 2023-09-13

该单中心病例系列纳入7例停用地舒单抗后发生反跳相关椎体骨折(RAVFs)的女性,再治疗24个月(地舒单抗3例、特立帕肽3例、唑来膦酸1例)。24个月时骨密度保持稳定或改善,无新发骨折,提示三种方案可能均适用,但需未来研究评估最合适方案。

要点

  • 7例RAVFs女性再治疗24个月,地舒单抗、特立帕肽或唑来膦酸组骨密度均稳定或改善。
  • 24个月随访期间无新发椎体或非椎体骨折。
  • 作者认为三种方案可能均适用,但需未来研究评估最合适方案。

核心结论

  • 在该RAVFs患者系列中,再治疗24个月后未观察到新发骨折,骨密度保持稳定。
  • 未来研究需要评估RAVFs后最合适的治疗方案,但这些初步数据提示地舒单抗、唑来膦酸和特立帕肽可能均为合适选择。

研究设计与样本

  • 单中心病例系列,纳入停用地舒单抗后发生反跳相关椎体骨折并接受再治疗24个月的患者。
  • 共纳入7例女性患者。

主要发现

  • 再治疗方案为地舒单抗(n=3)、特立帕肽(n=3)和唑来膦酸(n=1)。
  • 24个月时地舒单抗组骨密度平均变化:腰椎2.2%、股骨颈6.8%、全髋3.8%。
  • 24个月时特立帕肽组骨密度平均变化:腰椎7.5%、股骨颈1.4%、全髋3.7%。
  • 24个月时唑来膦酸组(1例)骨密度变化:腰椎5.0%、股骨颈0.6%、全髋3.9%。
  • 随访24个月后无患者发生新发骨折。

局限性

  • 未来研究需要评估RAVFs后最合适的治疗方案,这些数据为初步数据。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Evidence on the management of rebound-associated vertebral fractures after denosumab discontinuation is scarce. This study describes seven patients retreated with denosumab, teriparatide or zoledronate for 24 months. Their bone mineral density remained stable or improved and no new fractures occurred suggesting that all three options might be adequate for their treatment. PURPOSE: To describe the densitometric and biochemical changes achieved with osteoactive treatment after 24 months of follow-up in patients who suffered rebound-associated vertebral fractures (RAVFs) after Dmab discontinuation, and to report the occurrence of new vertebral and non-vertebral fractures. METHODS: Patients with RAVFs who received retreatment (RT) for 24 months were included. Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry at the lumbar spine (LS), femoral neck (FN) and total hip (TH), along with C-terminal cross-linked telopeptide of type I collagen, osteocalcin, and bone alkaline phosphatase. Data were collected at the start of the RT and after 24 months. RESULTS: Seven female patients were included. RT consisted in Dmab (n = 3), teriparatide (TPT) (n = 3) and zoledronate (Zol) (n = 1). At 24 months, the mean BMD change was 2.2% at LS, 6.8% at FN and 3.8% at TH in the Dmab group, 7.5% at LS, 1.4% at FN and 3.7% at TH in the TPT group and, 5.0% at LS, 0.6% at FN and 3.9% at TH in the patient with Zol. After 24 months of follow-up, no patient suffered new fractures. CONCLUSION: In this series of patients with RAVFs, we did not observe any new fractures and the BMD remained stable after 24 months of RT. Future studies are needed to evaluate the most suitable treatment approach after RAVFs but these preliminary data suggest that all denosumab, zoledronate and teriparatide might be adequate options.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Clifton Goldney D, Pelegrin C, Jerkovich F, et al. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series. Osteoporos Int. 2023. PMID: 37702746. doi:10.1007/s00198-023-06894-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。